Altimmune (3G0) Stock Price & Analysis

9 Followers

3G0 Stock Chart & Stats

€1.55€0.00(-10.42%)

At close: Nov 13 5:30 PM GMT+1

Day’s Range: EUR 1.48 - EUR 1.55
52-Week Range: EUR 1.47 - EUR 5.32
Previous Close: EUR 1.73
Volume: N/A
Average Volume (3M): 1,156
Market Cap: EUR 290.38M
Enterprise Value: EUR 358.18M
Total Cash (Recent Filing): EUR 265.06M
Total Debt (Recent Filing): EUR 36.20M
Price to Earnings (P/E): ―
Beta: 0.60
Next Earnings: Mar 03, 2027 (Est.)
EPS Estimate: -0.15
Next Dividend Ex-Date: N/A
Dividend Yield: N/A

Bulls Say, Bears Say

Bulls Say

Pemvidutide Clinical Differentiation

Pemvidutide has produced evidence across several clinically relevant liver measures, supporting differentiation beyond a single endpoint. If these findings translate into later-stage outcomes, the drug could address multiple aspects of MASH and strengthen Altimmune’s competitive position.

Liquidity Runway

A substantial cash position and stated runway through the planned MASH readout reduce near-term financing pressure while key trials advance. This gives management time to generate clinical data, preserve negotiating leverage, and pursue development without relying immediately on additional equity.

Broad Liver-disease Pipeline

Development across MASH, AUD and ALD creates a broader potential franchise around one therapeutic asset and related disease pathways. Multiple indications could diversify future commercialization opportunities and allow clinical, regulatory, and commercial capabilities to compound across programs.

Bears Say

Minimal Operating Revenue

The absence of an approved product leaves Altimmune dependent on financing and potential future partnerships rather than recurring operating revenue. Until a program reaches commercialization, the company cannot fund its substantial development platform through established product cash flows.

Persistent Cash Burn

Negative cash generation remains a structural feature of Altimmune’s development-stage model, and expanding clinical activity can increase funding needs before any product revenue arrives. Continued burn raises the importance of disciplined spending and future access to capital.

Clinical And Regulatory Execution Risk

Important value-creating milestones remain dependent on regulatory feedback, final trial design, funding decisions, and tolerability outcomes. Delayed or unfavorable developments could extend the path to commercialization, increase spending, and weaken the certainty of the broader pipeline thesis.

Altimmune News

Altimmune Earnings Call Highlights Pemvidutide Momentum

Altimmune (($ALT)) has held its Q3 earnings call. Read on for the main highlights of the call. Altimmune’s earnings call struck a strongly optimistic tone as management pointed to encouraging

17h agoALT 3G0

Altimmune price target lowered to $11 from $13 at B. Riley

B. Riley analyst William Wood lowered the firm’s price target on Altimmune (ALT) to $11 from $13 and keeps a Buy rating on the shares. Altimmune’s negative enterprise value and

2d agoALT 3G0

Altimmune reports Q3 EPS (15c), consensus (14c)

“We continue to make significant progress across all our clinical development programs, as we execute our strategy of building a liver franchise around pemvidutide” said Jerry Durso, Chief Executive Officer

3d agoALT 3G0

ALT Earnings this Week: How Will it Perform?

Altimmune (ALT) is scheduled to report 3rd quarter earnings on 11/12/2026, before the market opens. Regarding Q3 estimates, Wall Street analysts expect Altimmune to post earnings of -$0.13 per share.

5d agoALT 3G0

Altimmune says data from Reclaim Phase 2 trial to be presented at TLM

Altimmune (ALT) announced that a late-breaking abstract featuring results from the RECLAIM Phase 2 trial evaluating pemvidutide in adults with moderate-to-severe alcohol use disorder has been accepted as an oral

1w agoALT 3G0

Altimmune Draws New Loan Tranche to Extend Financing

Altimmune ( ($ALT) ) has provided an announcement. On October 27, 2026, Altimmune drew $10 million under the third tranche of its $125 million Loan and Security Agreement with Hercules

2w ago8K ALT

Altimmune refreshes board to support commercialization shift

Altimmune ( ($ALT) ) has issued an announcement. On October 27, 2026, Altimmune announced the appointment of seasoned biotech executives Peter Greenleaf and Alex Howarth to its board of directors,

2w ago8K ALT

Altimmune management to meet with Truist

Analyst Devarakonda holds a meeting with management. in Boston on October 8 hosted by Truist. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try

1M agoALT 3G0

Altimmune Appoints Richard Menziuso as Principal Accounting Officer

The latest update is out from Altimmune ( ($ALT) ). On September 24, 2026, Altimmune’s Board of Directors appointed Richard Menziuso as Vice President, Global Controller and Principal Accounting Officer,

1M ago8K ALT

Altimmune’s Phase 3 MASH Trial Puts Pemvidutide in the Spotlight for Investors

Altimmune ($ALT) announced an update on their ongoing clinical study. Altimmune, Inc. has launched a major Phase 3 study called “A Phase 3, Multinational, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to

1M agoALT

Altimmune price target lowered to $17 from $18 at Evercore ISI

Evercore ISI analyst Michael DiFiore lowered the firm’s price target on Altimmune (ALT) to $17 from $18 and keeps an Outperform rating on the shares. Peak sales expectations for Alcohol

1M agoALT 3G0

3 Under $10 Stocks With 150%+ Upside to Buy in September 2026, According to Analysts

Some low‑priced stocks have the potential to offer solid upside backed by clear catalysts. In September, three names under $10 stand out for strong pipelines and improving fundamentals, including Altimmune

2M agoALT KDK

Altimmune Charts Long Runway with Bold Trial Push

Altimmune (($ALT)) has held its Q2 earnings call. Read on for the main highlights of the call. Altimmune’s latest earnings call painted a broadly optimistic picture, with management emphasizing rapid

2M agoALT 3G0

Altimmune Maintained at Buy as Late-Stage Liver Programs Advance and $20 Price Target Remains Unchanged

Patrick Trucchio, an analyst from H.C. Wainwright, reiterated the Buy rating on Altimmune. The associated price target remains the same with $20.00. Patrick Trucchio has given his Buy rating due

3M agoALT 3G0

3G0 FAQ

What was Altimmune’s price range in the past 12 months?

Altimmune lowest stock price was €1.47 and its highest was €5.32 in the past 12 months.

What is Altimmune’s market cap?

Altimmune’s market cap is €290.38M.

When is Altimmune’s upcoming earnings report date?

Altimmune’s next earnings report is estimated for Mar 03, 2027 (not yet confirmed), which is in 108 days.

How were Altimmune’s earnings last quarter?

Altimmune released its earnings results on Nov 12, 2026. The company reported -€0.136 earnings per share for the quarter, missing the consensus estimate of -€0.12 by -€0.016.

Is Altimmune overvalued?

According to Wall Street analysts Altimmune’s price is currently Undervalued.

Does Altimmune pay dividends?

Altimmune does not currently pay dividends.

What is Altimmune’s EPS estimate?

Altimmune’s EPS estimate is -0.15.

How many shares outstanding does Altimmune have?

Altimmune has 194,589,450 shares outstanding.

What happened to Altimmune’s price movement after its last earnings report?

Altimmune reported an EPS of -€0.136 in its last earnings report, missing expectations of -€0.12. Following the earnings report the stock price went down -10.417%.

Which hedge fund is a major shareholder of Altimmune?

Hedge funds hold Altimmune shares: the largest hedge-fund position in Altimmune is 1,939,477,573 shares, and hedge funds increased their holdings by 16.6M shares last quarter.

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Altimmune Stock Smart Score

Neutral

Learn more about TipRanks Smart Score

Top Smart Score Stocks >

Company Description

Altimmune

Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on pioneering treatments for obesity and various liver diseases. Its primary investigational drug, pemvidutide (proposed INN, previously known as ALT-801), operates as a GLP-1/glucagon dual receptor agonist. This compound is currently undergoing Phase 1b clinical trials, exploring its efficacy in treating both obesity and non-alcoholic steatohepatitis (NASH). Additionally, Altimmune is advancing HepTcell, an immunotherapeutic candidate, through Phase 2 clinical trials. This therapy is designed for individuals suffering from chronic hepatitis B virus infection. The enterprise, initially named Vaxin Inc., officially adopted the Altimmune, Inc. moniker in September 2015. Established in 1997, the company maintains its corporate headquarters in Gaithersburg, Maryland.

Altimmune (3G0) Earnings & Revenues

Historic Earnings Reports

3G0 Earnings Call

Q3 2026

0:00 / 0:00

Earnings Call SentimentPositive

The call was strongly optimistic about pemvidutide's clinical differentiation and development progress. Management highlighted positive MASH and AUD data, expanding clinical execution, strong investigator engagement, a substantial AUD opportunity, and sufficient cash runway through the planned MASH readout. The principal negatives were higher operating expenses, a larger absolute quarterly net loss, low MASH diagnosis and treatment rates, ongoing tolerability evaluation, and the lack of a firm AUD Phase 3 start date or funding plan. Overall, the highlights significantly outweighed the lowlights.

View all DE:3G0 earnings summaries

3G0 Stock 12 Month Forecast

Average Price Target

€16.72▲(980.28% Upside)

Past 12 Months12 Month ForecastFeb2026Nov2026

High€18.08

Average€16.72

Low€15.37

Detailed Analyst Forecast >

Technical Analysis

Overall Consensus

Indicator	Bullish	Neutral	Bearish
Overall Consensus	5	3	14
Technical Analysis	5	3	2
Moving Averages	0	0	12

Technical Analysis >

Similar Stocks

Stocks similar to DE:3G0
Company	Price & Change	Follow
GALTGalectin Therapeutics
ARCTArcturus Therapeutics
ORMPOramed Pharm
SGMTSagimet Biosciences, Inc. Class A
BIOABioAge Labs, Inc.

Compare DE:3G0 Stocks >

Ownership Overview

0.48% Insiders
12.31% Mutual Funds
13.37% Other Institutional Investors
59.78% Public Companies and Individual Investors

Detailed Ownership Overview >

Popular Stocks

Popular Stocks
Company	Price & Change	Follow
NVDANvidia
AAPLApple
MSFTMicrosoft